Gilead Sciences (GILD) stock price, revenue, and financials

Gilead Sciences market cap is $86.6 b, and annual revenue was $24.69 b in FY 2020

$86.6 B

GILD Mkt cap, 11-Jun-2021

$6.4 B

Gilead Sciences Revenue Q1, 2021
Gilead Sciences Gross profit (Q1, 2021)5.1 B
Gilead Sciences Gross profit margin (Q1, 2021), %78.8%
Gilead Sciences Net income (Q1, 2021)1.7 B
Gilead Sciences EBIT (Q1, 2021)2.9 B
Gilead Sciences Cash, 31-Mar-20214.1 B
Gilead Sciences EV112.7 B

Gilead Sciences Revenue

Gilead Sciences revenue was $24.69 b in FY, 2020

Embed Graph

Gilead Sciences Revenue Breakdown

Embed Graph

Gilead Sciences revenue breakdown by business segment: 98.5% from Product Sales and 1.5% from Other

Gilead Sciences revenue breakdown by geographic segment: 17.0% from Europe, 74.1% from United States and 8.9% from Other

Gilead Sciences Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

26.1b22.1b22.4b24.7b

Revenue growth, %

(15%)1%

Cost of goods sold

4.4b4.9b4.7b4.6b

Gross profit

21.7b17.3b17.8b20.1b

Gross profit Margin, %

83%78%79%81%

R&D expense

3.7b5.0b9.1b5.0b

General and administrative expense

3.9b4.1b4.4b5.2b

Operating expense total

7.6b9.1b13.5b16.0b

EBIT

14.1b8.2b4.3b4.1b

EBIT margin, %

54%37%19%16%

Interest expense

523.0m1.1b995.0m

Pre tax profit

13.5b7.8b5.2b1.7b

Income tax expense

8.9b2.3b(204.0m)1.6b

Net Income

4.6b5.5b5.4b89.0m

EPS

3.54.24.2

Gilead Sciences Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

7.6b17.9b11.6b6.0b

Accounts Receivable

3.9b3.3b3.6b4.9b

Prepaid Expenses

1.7b1.6b1.4b2.0b

Inventories

801.0m814.0m922.0m1.7b

Current Assets

31.8b35.8b30.3b16.0b

PP&E

3.3b4.0b4.5b5.0b

Goodwill

4.2b4.1b4.1b8.1b

Total Assets

70.3b63.7b61.6b68.4b

Accounts Payable

814.0m790.0m713.0m844.0m

Short-term debt

2.7b2.7b2.5b2.8b

Current Liabilities

11.6b10.6b9.8b11.4b

Long-term debt

30.8b24.6b22.1b28.6b

Total Debt

30.8b24.6b24.6b31.4b

Common Stock

1.0m1.0m1.0m1.0m

Preferred Stock

Additional Paid-in Capital

1.3b2.3b3.1b3.9b

Retained Earnings

19.0b19.0b19.4b14.4b

Total Equity

20.5b21.5b22.7b18.2b

Debt to Equity Ratio

1.5 x1.1 x1.1 x

Debt to Assets Ratio

0.4 x0.4 x0.4 x

Financial Leverage

3.4 x3 x2.7 x3.8 x

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

10.3b8.7b11.5b7.6b13.2b14.6b16.9b11.2b9.5b10.1b6.7b12.9b4.1b

Accounts Receivable

4.0b4.5b4.1b3.8b3.5b3.5b3.3b3.4b3.3b3.9b3.2b3.9b3.9b

Prepaid Expenses

1.8b1.6b1.7b1.6b2.4b2.2b1.9b2.3b1.3b1.3b1.5b2.0b1.9b

Inventories

1.5b1.4b1.1b885.0m859.0m816.0m898.0m884.0m882.0m986.0m1.1b1.0b1.8b

Current Assets

21.4b28.6b35.3b30.3b32.7b34.9b34.0b33.7b28.4b27.0b24.6b30.9b13.3b

PP&E

2.9b3.0b3.1b3.4b3.7b3.8b4.1b4.2b4.4b4.6b4.7b4.8b5.0b

Goodwill

1.2b1.2b1.2b4.2b4.1b4.1b4.1b4.1b4.1b4.1b4.1b4.1b8.3b

Total Assets

57.7b60.3b64.7b65.4b65.4b64.3b62.8b63.2b59.1b59.7b55.9b60.9b67.5b

Accounts Payable

944.0m819.0m696.0m711.0m623.0m580.0m577.0m617.0m632.0m590.0m532.0m527.0m570.0m

Short-term debt

1.7b2.5b3.0b2.7b2.5b2.0b2.5b2.0b3.0b1.5b2.3b

Current Liabilities

8.3b8.5b9.6b10.7b10.9b10.1b9.4b9.0b9.6b8.9b10.6b9.5b9.7b

Long-term debt

26.3b26.3b27.5b26.6b26.1b24.6b24.1b24.1b22.1b22.1b21.1b27.8b27.9b

Total Debt

26.3b26.3b27.5b26.6b29.1b24.6b24.1b24.1b22.1b24.1b24.1b29.3b30.2b

Common Stock

1.0m1.0m1.0m1.0m1.0m1.0m1.0m1.0m1.0m1.0m1.0m1.0m1.0m

Preferred Stock

Additional Paid-in Capital

616.0m733.0m906.0m1.6b1.8b2.1b2.5b2.7b2.9b3.3b3.5b3.7b4.1b

Retained Earnings

19.6b21.8b23.7b19.2b19.8b20.7b19.3b19.8b17.6b18.7b14.4b13.7b14.8b

Total Equity

20.9b23.1b25.3b20.7b21.7b23.0b22.1b22.8b20.7b22.2b18.1b17.5b19.0b

Debt to Equity Ratio

1.3 x1.1 x1.1 x1.3 x1.3 x1.1 x1.1 x1.1 x1.1 x1.1 x1.3 x1.7 x

Debt to Assets Ratio

0.5 x0.4 x0.4 x0.4 x0.4 x0.4 x0.4 x0.4 x0.4 x0.4 x0.4 x0.5 x

Financial Leverage

2.8 x2.6 x2.6 x3.2 x3 x2.8 x2.8 x2.8 x2.9 x2.7 x3.1 x3.5 x3.6 x

Gilead Sciences Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

4.6b5.5b5.4b89.0m

Depreciation and Amortization

1.3b1.4b1.4b1.5b

Accounts Receivable

754.0m480.0m(218.0m)(1.2b)

Inventories

(253.0m)(310.0m)(95.0m)(195.0m)

Accounts Payable

(430.0m)(39.0m)(61.0m)80.0m

Cash From Operating Activities

11.9b8.4b9.1b8.2b

Purchases of PP&E

(590.0m)(924.0m)(825.0m)(650.0m)

Cash From Investing Activities

(16.1b)14.4b(7.8b)(14.6b)

Long-term Borrowings

(1.8b)(6.2b)(2.7b)(2.5b)

Dividends Paid

(2.7b)(3.0b)(3.2b)(3.4b)

Cash From Financing Activities

3.4b(12.3b)(7.6b)770.0m

Net Change in Cash

(641.0m)10.4b(6.3b)(5.6b)

Interest Paid

1.0b1.1b982.0m951.0m

Income Taxes Paid

3.3b3.2b1.8b2.6b

Gilead Sciences Ratios

USDQ1, 2017

Revenue/Employee

722.8k

Debt/Equity

1.3 x

Debt/Assets

0.5 x

Financial Leverage

2.8 x

Gilead Sciences Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019Sep, 2020Dec, 2020

Clinical Trials

138119104

Countries

30353535

Patent Applications (US)

393394

Patents (US)

642650

Phase I Trials Products (HIV / AIDS)

23

Phase I Trials Products (Inflammatory and Fibrotic Diseases)

14

Phase I Trials Products (Liver Diseases)

1

Phase I Trials Products (Oncology)

517

Phase I Trials Products (Viral Diseases)

3

Phase II Trials Products (HIV / AIDS)

1

Phase II Trials Products (Inflammatory and Fibrotic Diseases)

327

Phase II Trials Products (Liver Diseases)

33

Phase II Trials Products (Oncology)

432

Phase II Trials Products (Other)

11

Phase II Trials Products (Viral Diseases)

2

Phase III Trials Products

494127

Phase III Trials Products (HIV / AIDS)

11

Phase III Trials Products (Inflammatory and Fibrotic Diseases)

113

Phase III Trials Products (Liver Diseases)

11

Phase III Trials Products (Oncology)

311

Products

25272424

Gilead Sciences Sustainability Metrics

 FY, 2019

Total Recordable Incident Rate

0.45

Total Number of Recordable Work-related Injuries

58

Number of High-consequence Work-related Injuries

4

Number of Fatalities

0

Gilead Sciences Human Capital

Ethnicity

FY, 2019FY, 2018
Asian (USA), percent38%36.6%
Hispanic / Latino (USA), percent11%10.9%
White (USA), percent42%43.6%
Other9%8.9%

Gender

FY, 2019FY, 2018
Male (Mid-level Executives), percent17%17%
Female (Mid-level Executives), percent16.3%16.3%
Female (USA), percent17%17%
Female (Executive Leadership), percent11%10.3%
Male (USA), percent16.3%16.3%
Male (Executive Leadership), percent22.3%23%

Gilead Sciences Employee Rating

3.81290 votes
Culture & Values
3.4
Work/Life Balance
3.2
Senior Management
3.1
Salary & Benefits
4.1
Career Opportunities
3.2
Source